Sticking It to Cancer with Molecular Glue for SHP2

Hao Ran; Ryouhei Tsutsumi; Toshiyuki Araki; Benjamin G Neel

doi:10.1016/j.ccell.2016.07.010

Sticking It to Cancer with Molecular Glue for SHP2

Cancer Cell. 2016 Aug 8;30(2):194-196. doi: 10.1016/j.ccell.2016.07.010.

Authors

Hao Ran¹, Ryouhei Tsutsumi¹, Toshiyuki Araki¹, Benjamin G Neel²

Affiliations

¹ Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA.
² Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA. Electronic address: benjamin.neel@nyumc.org.

Abstract

Much effort has been expended to develop inhibitors against protein-tyrosine phosphatases (PTPs), nearly all of it unsuccessful. A recent report, describing a highly specific, orally bioavailable inhibitor of the PTP oncoprotein SHP2 with in vivo activity, suggests that allostery might provide a way forward for PTP inhibitor development.

Publication types

Comment

MeSH terms

Animals
Humans
Mice
Molecular Targeted Therapy
Neoplasms / drug therapy*
Neoplasms / enzymology
Neoplasms / genetics
Protein Kinase Inhibitors / pharmacology*
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / antagonists & inhibitors*
Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics

Substances

Protein Kinase Inhibitors
Protein Tyrosine Phosphatase, Non-Receptor Type 11

Grants and funding

R01 CA049152/CA/NCI NIH HHS/United States